* patients who are already on statins or nicorandil. * patients labeled as having mild, moderate or severe covid-19 infection as per the fda definitions. * patients with shock as defined by sbp\<90 for more than 30 minutes not responding to iv fluids with evidence of end organ damage. * severe hepatic impairment (child-pugh class c) or active liver disease are absolute reasons not to be included especially those with unexplained persistent elevations of serum transaminases. * pregnancy or breastfeeding * hypersensitivity to any of the above-mentioned medications * on levodopa. * patients on pde5 inhibitors, riociguat * acute pulmonary edema * hypovolemia * leber's disease

* patients who are already on statins or nicorandil. * patients labeled as having mild, moderate or severe covid-19 infection as per the fda definitions. * patients with shock as defined by sbp\<90 for more than 30 minutes not responding to iv fluids with evidence of end organ damage. * severe hepatic impairment (child-pugh class c) or active liver disease are absolute reasons not to be included especially those with unexplained persistent elevations of serum transaminases. * pregnancy or breastfeeding * hypersensitivity to any of the above-mentioned medications * on levodopa. * patients on pde5 inhibitors, riociguat * acute pulmonary edema * hypovolemia * leber's disease

- patients who are already on statins or nicorandil. - patients labeled as having mild, moderate or severe covid-19 infection as per the fda definitions. - patients with shock as defined by sbp<90 for more than 30 minutes not responding to iv fluids with evidence of end organ damage. - severe hepatic impairment (child-pugh class c) or active liver disease are absolute reasons not to be included especially those with unexplained persistent elevations of serum transaminases. - pregnancy or breastfeeding - hypersensitivity to any of the above-mentioned medications - on levodopa. - patients on pde5 inhibitors, riociguat - acute pulmonary edema - hypovolemia - leber's disease

- patients who are already on statins or nicorandil. - patients labeled as having mild, moderate or severe covid-19 infection as per the fda definitions. - patients with shock as defined by sbp<90 for more than 30 minutes not responding to iv fluids with evidence of end organ damage. - severe hepatic impairment (child-pugh class c) or active liver disease are absolute reasons not to be included especially those with unexplained persistent elevations of serum transaminases. - pregnancy or breastfeeding - hypersensitivity to any of the above-mentioned medications - on levodopa. - patients on pde5 inhibitors, riociguat - acute pulmonary edema - hypovolemia - leber's disease